When diabetic macular edema involves the center of the macula (CI-DME), the risk of significant visual loss is at its highest. This specific classification — center-involved vs. non-center-involved DME — directly determines which treatment path is appropriate.
Diabetic macular edema is classified as either center-involved (CI-DME) or non-center-involved (NCI-DME). Because visual loss risk is greatest when edema is located at the center of the macula, this distinction is essential to clinical decision-making and defines the indication for first-line intervention.
Intravitreal anti-VEGF therapy has displaced focal laser surgery as the first-line treatment for CI-DME, supported by multiple high-quality clinical trials demonstrating superior visual outcomes. Treatment timing may be adjusted based on the patient's current visual acuity — the full decision algorithm, agent selection, and follow-up schedule are detailed in the complete protocol.
The primary objectives are improvement in vision and reduction in central macular thickness, with resolution of macular edema and achievement of 20/20 visual acuity as key endpoints. Response assessment may begin as early as one month after treatment initiation.